Dr. Dineo Khabele, Professor and Chair of the Department of Obstetrics & Gynecology at Washington University School of Medicine in St. Louis and member of OCRA’s Scientific Advisory Committee, spoke at our 2020 Ovarian Cancer National Conference about the racial disparities in ovarian cancer incidences and outcomes. While there are more documented cases of ovarian … Continued
Despite the challenges of fundraising during a global pandemic, your generous support allowed us to fund 16 top scientists at 14 esteemed medical centers across the globe. They will investigate important issues across the ovarian cancer landscape in this coming year. These grants enable the brightest minds in cancer research to tackle long-standing issues like … Continued
OCRA-funded researcher Anil K. Sood, M.D., lead and senior author, and Sanghoon Lee, Ph.D., first author, both at MD Anderson Cancer Center, along with colleagues, identified potential biomarkers in subgroups of high-grade serous ovarian cancer (HGSC). Biomarkers are unique biological indicators of an event, or the presence of a substance in the body. Biomarkers are useful … Continued
The rollout of COVID-19 vaccines in the United States has many feeling hopeful about the possibility of gaining some protection against the virus. But as with any new medical advancement, it is not uncommon for people to have questions about its safety and efficacy. And for those who are living with ovarian cancer, there are … Continued
A recent study, published in Cancer Research and reported in The New York Times, suggests that risk-reduction associated with oral contraceptive use can last a lifetime. The link between lower ovarian and endometrial cancer risk and oral contraceptive use has long been established; however, it was unclear how long after taking oral contraceptives a woman … Continued
It’s hard to believe 2020 is almost over, and what a year it’s been. Despite the challenges wrought by the pandemic, we’re grateful to report that thanks to your support, OCRA grantees made great strides in ovarian cancer discoveries, bringing us ever closer to improving care and defeating this devastating disease: Revealed two cells of origin for high-grade serous ovarian cancer — … Continued
We’re probably all ready to say goodbye to 2020, if we have to be honest with ourselves. And yet, we can’t look back and say that the year was entirely bad. With your support, OCRA actually accomplished quite a lot and we have much for which to feel hopeful. RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS WAYS TO GIVE … Continued
OCRA-funded researchers Dr. Sunila Pradeep and Dr. Pradeep Chaluvally-Raghavan, both at the Medical College of Wisconsin, along with colleagues, summarized recent literature on the function of extracellular vesicles “in regulating the critical processes associated with cancer progression.” Their review, published in the journal Cancers, also provides insights on how these vesicles are used as biomarkers … Continued
Could the next ovarian cancer breakthrough be traced back to a Commodore 64 home computer? After all, in some small measure, OCRA grantee Dr. Sohrab Shah is where he is today thanks to that now-antiquated instrument. He was 11 or 12 years old, tinkering around with programming at home, when he became captivated with what … Continued
An international collaborative of scientists, including Dr. Ronald Chandler at Michigan State University, studied ARID1A mutations, which are specific gene mutations observed in deep ovarian and deep infiltrating endometriosis. The authors of the study noted that seeing a high frequency of these mutations in deep ovarian endometriosis supports evidence linking this to endometriosis-associated ovarian cancer. … Continued
We’re full on into fall, and giving thanks for all that we’ve accomplished together, in a year that’s been more than a little challenging. RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS EVENTS WAYS TO GIVE
A bright spot in 2020 for the ovarian cancer community has been the ongoing developments in research and treatments. Advances continue to be made, as researchers study the effectiveness of PARP inhibitors as maintenance therapy for ovarian cancer, the most effective way to implement immunotherapy agents, the key factors that can affect the success of … Continued
Get email updates about research news, action alerts, and ways to join the fight.
